Alumis sets out IPO ambitions to fund TYK2 inhibitor through phase 3 psoriasis trials 10.06.2024 13:29 Fiercebiotech.com Alumis sets out IPO ambitions to fund TYK2 inhibitor through phase 3 psoriasis trials jwaldron Mon, 06/10/2024 - 06:29
